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PRM225  
MODELING AND ANALYTICS FRAMEWORK FOR VALUE BASED PRICING  
Dinh T1, Newton M2 
1Archimedes Inc., San Francisco, CA, USA, 2Archimedes Inc, San Francisco, CA, USA  
Pharmaceutical companies and payers increasingly engage in value-based 
pricing agreements, which link payment for a medicine to value achieved. 
However, the traditional approach to drug development has been oriented 
towards efficacy and safety and is unable to address the evidence requirements 
from payers and health technology assessors. To support this emerging 
paradigm change in drug development, Archimedes has developed a systematic 
framework that integrates evidence (randomized clinical trials, electronic 
medical records, claims, laboratory results, disease registries) with analytics and 
modeling (predictive modeling, health-economic simulation, cost-effectiveness 
analysis) to provide a comprehensive assessment of all health and economic 
benefits of new interventions – including potential cost savings elsewhere in the 
treatment pathways, improvements in quality of life of patients and caregivers 
as well as other societal benefits. The framework leverages the strength of  
the Archimedes ARCHES Simulation platform as well as a suite of analytic tools 
and services developed specifically to capture values of interventions. It  
also enables probabilistic sensitivity analysis and uncertainty quantification  
of predicted values. The framework is designed to integrate organically with  
the life-cycle of product development. It will help the pharmaceutical companies 
to establish the value-based evidence-generation process, identify 
subpopulations for which their medications are most valuable, and evaluate 
commercial value of new medications as early as possible in the development 
cycle. In this presentation, we will present the key elements of the framework as 
well as the results of a case study, in which the framework is used to  
support value-based pricing for a novel intervention. We will demonstrate how 
costs and benefits of the intervention vary across different subpopulations, 
suggesting a multi-tiered pricing approach may be the optimal strategy for the 
intervention.  
 
PRM226  
A MULTIPLE CRITERIA DECISION ANALYSIS FRAMEWORK FOR VALUE BASED 
ASSESSMENT OF NEW MEDICAL TECHNOLOGIES  
Angelis A, Kanavos P 
London School of Economics and Political Science, London, UK  
The use of cost/QALY has been criticised for a variety of reasons, including the 
fact that the QALY does not capture adequately elements associated with burden 
of disease, aspects of product’s innovation level, and wider socioeconomic 
implications. No such ‘holistic’ value based assessment (VBA) method has been 
successfully created yet. Using Multiple Criteria Decision Analysis (MCDA) we 
develop a new methodological framework for assessing the value of new medical 
technologies according to the following procedure: Establish the decision 
context; the decision perspective could potentially adopt a health system’s 
societal point of view. Identify the options; choose the candidate technologies to 
be assessed, e.g. antineoplastic drugs for metastatic colorectal cancer. Identify 
the value objectives/criteria; these should include several technology – disease 
characteristics and could be divided in the areas of: a) burden of illness; b) 
therapeutic improvement; c) quality of life benefits; d) innovation level; and e) 
socioeconomic impact. ‘Scoring’; assess the value associated with the 
consequences of each criterion for each option, e.g. by adopting a direct rating 
approach where the judgment of experts is used to rank the magnitude of value. 
‘Weighting’; assign weights for each of the criteria to reflect their relative 
importance to the decision, e.g. by using a swing weighting method 
implemented in combination with a nominal-group technique where experts 
agree on the relative contribution of each criterion. Produce a value index; 
combine weights and scores for each option to derive an overall index of value, 
e.g. through a weighted average linear additive model. Examine the results and 
conduct a sensitivity analysis; test the impact of changes in scores and weights 
on the overall value. The result would subsequently provide evidence on the 
value of each technology. The methodology could then be applied more 
practically by linking value index scores with reimbursement and/or pricing 
decisions.  
 
PRM227  
CONSIDERATIONS IN THE APPPLICATION OF NOVEL STATISTICAL METHODS 
FOR CROSSOVER ADJUSTMENT IN TRIALS OF CANCER TREATMENTS  
Ishak KJ1, Proskorovsky I1, Korytowsky B2, Sandin R3 
1United BioSource Corporation, Dorval, QC, Canada, 2Pfizer Global Pharmaceuticals, New York, 
NY, USA, 3Pfizer Global Pharmaceuticals, Sollentuna, Sweden  
Rank Preserving Structural Failure Time (RPSFT) and Inverse Probability of 
Censoring Weighted (IPCW) models are increasingly applied to adjust for bias in 
treatment effect estimates in trials of cancer drugs where crossover to the new 
treatment is allowed. We review the assumptions and processes underlying 
these methods and their suitability in different situations using a case study. A 
first consideration is the meaning of the cross-over adjusted result, which is an 
estimate of the treatment effect had crossover not occurred – i.e., if patients had 
continued to be treated with standard therapy. This may be plausible when no 
other treatment options are available; otherwise, the crossover-adjusted 
estimate becomes a theoretical upper-bound, and likely not representative of 
real-world effectiveness. The assumptions inherent to each approach must also 
be considered carefully. For instance, RPSFT models shrink the survival time of 
patients who cross-over by a magnitude proportional to the time spent on the 
experimental drug and its associated benefit. Implied here is that patients derive 
the same benefit for every unit of time on the experimental treatment, and that 
this benefit is the same in both the original randomized population and those 
who cross over. The latter are selected, however, based on their expected 
responsiveness to and tolerance of the new treatment. In the IPCW approach 
adjustment is made by analytically matching patients who cross over to patients 
who had a similar prognosis but did not crossover. The prognosis of these groups 
may not overlap sufficiently, however; in fact, full characterization of the 
prognosis of patients may be impossible as it requires time-dependent 
information on factors considered by physicians deciding which patients should 
cross over. This talk aims to promote better understanding of these methods, 
their proper application and interpretation and use of results.  
 
PRM228  
NICE'S SELECTIVE APPLICATION OF DIFFERENTIAL DISCOUNTING: 
AMBIGUOUS, INCONSISTENT AND UNJUSTIFIED  
O'Mahony J1, Paulden M2 
1Trinity College Dublin, Dublin, Ireland, 2University of Toronto, Toronto, ON, Canada  
The National Institute for Health and Clinical Excellence (NICE) recently 
recommended differential discounting of costs and health effects in the 
economic appraisal of health care interventions in certain circumstances. The 
recommendation was published in an amendment to NICE’s guide to the 
methods of technology appraisal. The amendment states that differential 
discounting should be applied where “treatment effects are both substantial in 
restoring health and sustained over a very long period (normally at least 30 
years)”. Renewed interest in differential discounting from NICE is welcome; 
however, the recommendation’s selective application of differential discounting 
raises a number of concerns. The stated criteria for applying differential 
discounting are ambiguous. The rationale for the selective application of 
differential discounting has not been articulated by NICE and is questionable. 
The selective application of differential discounting leads to several 
inconsistencies, the most concerning of which is the lower valuation of health 
gains for those with less than 30 years remaining life expectancy, which can be 
interpreted as age discrimination. Furthermore, the discount rates chosen by 
NICE do not appear to be informed by recent advances in the theoretical 
understanding of differential discounting. NICE’s apparent motivation for 
recommending differential discounting was to ensure a favourable cost-
effectiveness ratio for a paediatric oncology drug. While flexibility may be 
appropriate to allow some interventions that exceed conventional cost-
effectiveness thresholds to be adopted, the selective adjustment of appraisal 
methods is problematic and without justification.  
 
PRM229  
THE CASE-REFERENT STUDY: ARE DIFFICULTIES IN ITS REPORTING AND 
INTERPRETATION AFFECTING NON-RCT SYSTEMATIC REVIEWS?  
WOULD AN EXTENSION TO STROBE HELP?  
MacGilchrist KS1, Bhopal RS2 
1Abacus International, Bicester, UK, 2Centre for Population Health Sciences University of 
Edinburgh, Edinburgh, UK  
BACKGROUND: The quality of evidence provided by systematic reviews rests on 
clear reporting in original papers. A STROBE checklist aids reporting of case-
control studies, but does not distinguish different case-referent designs. These 
latter include case-base, incidence density and case-exposure designs, as well as 
the (traditionally understood) case-control study. The measure estimated and, if 
an odds ratio, how that may be interpreted, is dependent upon the design. In 
spite of methodology elaborated over four decades, a 2000 review identified 
numerous difficulties with authors’ reporting and interpretation of case-referent 
studies, and a review a decade later indicated that such issues prevailed. 
OBJECTIVE: To provide guidance on reporting of case-referent studies. 
METHODS: Medline search in 2000 for odds ratio, relative risk, rare disease 
assumption and rarity assumption; review of collection of articles from R. 
Bhopal; snowballing. RESULTS: 1) State the reference series sampling scheme. 
Cumulative incidence (traditional or exclusive), incidence density (concurrent) or 
case-base (inclusive), sampling. 2) State whether incident and/or prevalent cases 
enrolled 3) State what your case-referent study is calculating. A true odds ratio 
will only result from a case-controlstudy. Incidence density sampling, where the 
reference series is used to calculate population time, yields an incidence density 
ratio and case-base sampling enables direct calculation of a risk ratio. 4) State 
the formal assumptions made or formulae used 5) Refrain from ‘labelling’ effect 
measures relative risk (especially in the abstract). CONCLUSION: For case-
referent studies to be incorporated into systematic reviews authors should report 
and editors should require greater technical detail. Would an extension of 
STROBE help?  
 
DISEASE-SPECIFIC STUDIES 
 
MENTAL HEALTH – Clinical Outcomes Studies 
 
PMH1  
COMPARATIVE EFFECTIVENESS OF ANTIPSYCHOTICS AND VALPROATE 
VERSUS ANTIPSYCHOTIC USE ALONE ON THE RISK OF LONG-TERM CLINICAL 
OUTCOMES AND MORTALITY IN THE ELDERLY POPULATIONS WITH 
SCHIZOPHRENIA  
Parente A, Teigland C, Jones B, Mehta S, Chen P, Yang X, Scoggins J 
Inovalon Inc., Bowie, MD, USA  
OBJECTIVES: To evaluate the relative likelihood of cardiac events, pancreatitis, 
pneumonia, and death associated with use of valproate (V) as an adjunct  
“off label” therapy to antipsychotics (AP) in the elderly population with 
schizophrenia. METHODS: This retrospective cohort study utilized a propensity-
score matching technique and a new user design to identify patients in a large 
nationally representative administrative database. The sample included 
Medicaid, Medicare, and Commercial patients aged 65+ with a diagnosis  
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of schizophrenia who were continuously enrolled with pharmacy coverage for 
12-months before treatment initiation. Patients with a diagnosis of bipolar, 
epilepsy or migraine were excluded. The AP cohort was identified by the first 
prescription fill with no prior use in previous 12-months. The combination 
therapy cohort (V+AP) was identified by the first prescription fill for V and an AP 
fill within 30 days. Multivariate survival analysis was used to follow patients to 
first adverse event or up to six years after index date to assess relative risk of 
adverse events. RESULTS: The study population included 1,348 patients treated 
with V+AP (female=52.6%, age=79.3 (± 6.9); history: liver disorder=5.9%, 
congestive heart failure=28.5%, peripheral arterial disease=32.2%) and 1,348 AP 
only patients (female=50.3%, age=79.1 (± 6.8); history: liver disorder=14.3%, 
congestive heart failure=27.9%, peripheral arterial disease=34.3%). Patients 
treated with AP only had a significantly lower risk of cerebrovascular disease 
(HR=0.65, 95% CI: 0.51-0.85, p=0.01) after controlling for potential confounders. 
Adding V did not increase risk of other outcomes evaluated. CONCLUSIONS: 
Clinical trials have failed to provide evidence of the efficacy of V as an adjunct 
therapy to AP to treat schizophrenia, but “off-label” prescribing of V+AP remains 
high. This study provides new evidence to inform prescribing practices in elderly 
patients with schizophrenia. The increased risk of stroke must be weighed 
against any incremental benefit to the patient that the addition of V may 
provide.  
 
PMH2  
ANTIPSYCHOTIC USE AND RISK OF PNEUMONIA IN ELDERLY NURSING HOME 
RESIDENTS: A PROPENSITY-MATCHED STUDY  
Chatterjee S, Aparasu RR, Chen H 
University of Houston, Houston, TX, USA  
OBJECTIVES: Antipsychotic medications are extensively used in nursing homes 
for management of behavioral and psychiatric disorders in the elderly. Prior 
research suggests that pneumonia is one of the common causes of 
antipsychotic-related mortality in this population. None of the studies compared 
typical and atypical antipsychotics with respect to pneumonia. This study 
examined the risk of pneumonia with use of typical versus atypical 
antipsychotics in dual eligible elderly nursing home residents. METHODS: The 
study involved a retrospective cohort design matched on propensity score using 
Medicare and Medicaid Analytical eXtract (MAX) data from four US states. The 
study population included elderly dual eligible (Medicaid and Medicare) nursing 
home residents (aged > 65 years) who initiated antipsychotics anytime during 
July 1, 2001 and December 31, 2003. The risk of pneumonia during the 6-month 
follow-up period was modeled using Cox proportional model and extended Cox 
hazard model stratified on matched pairs based on propensity scores, using 
atypical agents as the reference category. RESULTS: Analysis of Medicaid-
Medicare data revealed that there were 49,904 antipsychotic (46,293 atypical and 
3,611 typical) users in the unmatched cohort and 7,218 (3,609 atypical and 3,609 
typical) users in the matched cohort. The unadjusted rate of pneumonia was 
8.17% (295) for atypical users and 5.21% (188) for typical users. The results of Cox 
regression [average Hazards Ratio, HR, 1.24; 95% CI, 0.94-1.64] and extended 
regression [<50 days: HR, 1.17; 0.83-1.66 and 50-180 days: HR, 1.36; 0.87-2.14] 
suggest that, there was no difference in risk of pneumonia among typical  
and atypical users. CONCLUSIONS: The study found no differential risk  
of pneumonia among typical versus atypical antipsychotic use in dual eligible 
nursing home residents. Given the differential risk of mortality with typical  
and atypical use in nursing homes, more research is needed to evaluate  
other contributory factors of mortality with respect to these two antipsychotic 
classes.  
 
PMH3  
RECURRENT STROKE RISK ASSOCIATED WITH ANTIDEPRESSANT USE IN  
POST-STROKE PATIENTS  
Wang MT, Chu CL 
National Defense Medical Center, Taipei, Taiwan  
OBJECTIVES: Despite depression as the most frequent neuropsychiatric 
consequence of stroke, empirical safety evidence of antidepressant use in post-
stroke patients is absent. This study aimed to assess the risk of recurrent stroke 
by antidepressant use among patients with first-ever stroke. METHODS: A 
nested case-control study was performed among patients with first stroke 
analyzing data extracted from the National Health Insurance Research Database 
between 01/01/2000 and 12/31/2008. Cases identified as patients with recurrent 
stroke were individually matched with up to two randomly-selected controls by 
age, sex, and cohort entry date using an incidence density sampling approach. 
Conditional logistic regression was employed to estimate the recurrent stroke 
risk associated with selective serotonin reuptake inhibitors (SSRIs), tricyclic 
antidepressants (TCAs) and “other antidepressants”, as well as to assess the 
impact of dose, duration and recency of antidepressant therapy. RESULTS: The 
study cohort comprised 24,107 patients with first stroke, in which 4,415 cases 
were identified and matched to 8,294 randomly-selected controls. There was no 
statistically increased risk for any use of SSRIs (adjusted odds ratio [OR] = 0.99; 
95% CI, 0.78-1.26), TCAs (adjusted OR = 1.12; 95% CI, 0.96-1.30), or “other 
antidepressants” (adjusted OR = 1.10; 95% CI, 0.90-1.34). The insignificant risk for 
SSRIs remained regardless of varying dose, duration and recency of the therapy. 
However, short-term use of TCAs (≤ 30 days), discontinued TCA therapy in the 1-
30 days and 31-90 days preceding the index date was related to a 1.22-fold (95% 
CI, 1.01-1.49), 1.71-fold (95% CI, 1.18-2.48) and 1.50-fold (95% CI, 1.03-2.20) 
increased risk, respectively. The increased risk by use of “other antidepressants” 
was confined to short-term use (≤ 30 days; adjusted OR = 1.40; 95% CI, 1.07-1.81). 
CONCLUSIONS: Discontinued TCA therapy, short-term use of TCAs and “other 
antidepressants” all increase the recurrent stroke risk in post-stroke patients, 
which warrants clinical vigilance.  
PMH4  
EVALUATION OF CLINICAL AND TREATMENT CHARACTERISTICS AND THE 
ECONOMIC BURDEN OF ANXIETY IN VETERAN PATIENTS IN THE UNITED 
STATES  
Wang L1, Zhang J1, Baser O2 
1STATinMED Research, Dallas, TX, USA, 2STATinMED Research/The University of Michigan, 
Ann Arbor, MI, USA  
OBJECTIVES: To assess the clinical and treatment characteristics as well as 
economic burden of anxiety patients in the U.S. veteran population. METHODS: 
A retrospective analysis was performed using the Veterans Health 
Administration (VHA) Medical SAS Datasets from October 1, 2005 to May 31, 2012. 
All U.S. veteran beneficiaries diagnosed with anxiety were identified using 
International Classification of Disease 9th Revision Clinical Modification (ICD-9-
CM) diagnosis code 300.xx. Comorbid condition status was examined for the 12-
month baseline period before disease identification, and treatment patterns 
were examined for the period between the disease identification date and 60 
days after the identification date. Health care utilization and costs were 
measured in the 12-month follow-up period. RESULTS: A total of 687,325 
patients were diagnosed with anxiety. Common comorbidities included 
hypertension (n=165,086, 24.02%), depressive disorder (n=99,736, 14.51%), post-
traumatic stress disorder (n=92,514, 13.46%) and diabetes (n=89,041, 12.95%). The 
top treatments were simvastatin (n=139,001, 20.22%), citalopram hydrobromide 
(n=118,280, 17.21%), omeprazole (n=112,032, 16.30%), and lisinopril (n=103,489, 
15.06%). Other available treatments were trazodone, sertraline hydrochloride, 
lorazepam, hydrochlorothiazide and aspirin. The numbers of anxiety patients 
with inpatient, outpatient and pharmacy visits were 136,109 (19.80%), 686,307 
(99.85%) and 649,999 (94.57%), respectively, and related costs were $6,586 
(standard deviation [SD]=$32,770), $8,831 (SD=$12,369) and $1,576 (SD=$10,109). 
CONCLUSIONS: U.S. veterans diagnosed with anxiety frequently experienced 
comorbidities such as hypertension, depressive disorder, post-traumatic stress 
disorder, and diabetes in the 1-year baseline period. Future treatment regimen 
choices may need to address anxiety within the context of these comorbidities.  
 
PMH5  
EFFECTIVENESS OF OLANZAPINE IN THE TREATMENT OF SYMPTOMATIC 
SCHIZOPHRENIA PATIENTS WHO SWITCHED FROM CONVENTIONAL 
ANTIPSYCHOTICS IN CHINA  
Montgomery W1, Ye WW2, Kadziola Z3, Treuer T4, Liu LL5, Xue HBH2, Wu SH2,  
Ascher-Svanum H6 
1Eli Lilly Australia, West Ryde NSW, Australia, 2Lilly Suzhou Pharmaceutical Co., Ltd. Shanghai 
Branch, Shanghai, China, 3Eli Lilly and Company, Vienna, Austria, 4Eli Lilly & Company, 
Budapest, Hungary, 5Lilly Suzhou Pharmaceutical Co., Ltd., Shanghai, P.R. China, China,  
6Eli Lilly & Co., Indianapolis, IN, USA  
OBJECTIVES: To investigate the outcomes of patients with schizophrenia who 
lacked symptomatic control with conventional antipsychotics who were 
switched to olanzapine. METHODS: A post-hoc analysis was conducted on the 
China subgroup (n=475) of a multi-country, 12-month, prospective, non-
interventional observational study. Outcome measures included: Brief 
Psychiatric Rating Scale (BPRS), Clinical Global Impressions-Severity (CGI-S), 
Abnormal Involuntary Movements Scale (AIMS) and the brief WHO-Quality of 
Life Scale (WHO-QoL-BREF). Mixed models for repeated measures controlling for 
baseline scores, gender, age, baseline weight, and investigator were used to 
assess outcomes. RESULTS: Mean baseline CGI-S was 5.02 (95% C.I.: 4.94, 5.11). 
Most patients responded to olanzapine - 97% (95% C.I.: 94%, 98%) defined as a 
reduction in BPRS total score at endpoint by ≥30% relative to baseline. Significant 
improvements were observed in clinical status. LsMean change in BPRS total at 
month 12 from baseline was -33.3 (95% C.I.: -33.9, -32.8), and -3.4 for CGI-S (95% 
C.I.: -3.5, -3.3). Quality of life improved significantly for all domains of the WHO 
QoL-BREF. LsMean changes (improvements) from baseline to month 12 were: 
Physical 26.1(95% C.I.: 25.1, 27.2), Psychological 28.9 (95% C.I.: 27.6, 30.2), Social 
26.1 (95% C.I.: 24.5, 27.6) and Environment 24.3 (95% C.I.: 23.0, 25.6). Mean 
olanzapine dose at endpoint was 7.6mg (range 2.5, 25.0mg). AIMS score 
decreased from 3.9 to 0.3 (p<.0001) over the course of the study. Olanzapine 
treatment was associated with a mean weight gain of 4.2kg (95% C.I.:3.8, 4.6), and 
43% (95% C.I.: 38%, 48%) gained ≥7% of their baseline weight over 12 months. 
CONCLUSIONS: This post-hoc analysis suggests that for patients from mainland 
China with schizophrenia who are still symptomatic, despite previous treatment 
with conventional antipsychotics, switching to olanzapine may result in 
additional benefits in terms of further improvement in symptoms and quality of 
life, and a reduction in abnormal involuntary movements.  
 
PMH6  
A DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIAL OF 
ADJUNCTIVE ARMODAFINIL FOR THE TREATMENT OF MAJOR DEPRESSION 
ASSOCIATED WITH BIPOLAR I DISORDER  
Frye MA1, Ketter TA2, Yang R3, Calabrese JR4 
1Mayo Clinic, Rochester, MN, USA, 2Stanford University School of Medicine, Stanford, CA, USA, 
3Teva Pharmaceutical Industries Ltd., Frazer, PA, USA, 4University Hospitals Case Medical 
Center, Cleveland, OH, USA  
OBJECTIVES: The goal of this study was to evaluate the efficacy and safety of 
armodafinil as an adjunctive therapy for major depression associated with 
bipolar I disorder. METHODS: Patients 18-65 years of age with bipolar I disorder 
currently experiencing a major depressive episode while taking 1 or 2 mood 
stabilizer(s) and/or second-generation antipsychotics were randomized. The 
primary outcome was the mean change from baseline to week 8 in the 30-item 
Inventory of Depressive Symptomatology–Clinician-rated (IDS-C30) total score. 
RESULTS: 433 patients were randomized (n=199 placebo, n=201 armodafinil 150 
mg, n=33 armodafinil 200 mg). Randomization to the 200 mg armodafinil group 
